Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury

NCT03296761 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2017-11-01

No results posted yet for this study

Summary

To observe the changes of plasma ESM-1 levels in patients with ARDS, and to explore its clinical significance.

Conditions

  • Evaluate the Correlation Between the Level of ESM-1 and the Prognosis of the Patients With ARDS

Sponsors & Collaborators

  • Jingyuan,Xu

    lead OTHER

Principal Investigators

  • Haibo qiu · Zhong-Da Hospital, School of Medicine, Southeast University,

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2017-12-20
Completion
2018-02-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03296761 on ClinicalTrials.gov